Immediate Impact
29 standout
Citing Papers
Current and future immunotherapeutic approaches in pancreatic cancer treatment
2024 Standout
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Works of Mona Elshafie being referenced
Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort
2021
Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Mona Elshafie | 159 | 138 | 75 | 77 | 21 | 367 | |
| Ann A. Browder | 73 | 39 | 43 | 29 | 20 | 327 | |
| Michael Friedland | 31 | 99 | 58 | 27 | 24 | 389 | |
| Phillip Ruiz | 85 | 32 | 58 | 88 | 14 | 342 | |
| Stylianos Vagios | 120 | 78 | 113 | 8 | 35 | 408 | |
| Teeranan Angkananard | 106 | 128 | 47 | 35 | 17 | 347 | |
| Habib Çil | 68 | 175 | 113 | 30 | 21 | 400 | |
| Nuri Köse | 74 | 125 | 64 | 33 | 28 | 369 | |
| Arvind Bakhru | 52 | 58 | 60 | 14 | 13 | 411 | |
| P. Capel | 33 | 28 | 41 | 60 | 27 | 348 | |
| Gustavo Adolpho Moreira Faulhaber | 46 | 31 | 41 | 54 | 32 | 369 |
All Works
Loading papers...